Last updated: February 21, 2026
What is the scope of patent CA2610708?
Patent CA2610708 covers a pharmaceutical invention aimed at treatment or prevention of a specific medical condition, likely involving a novel compound, formulation, or method. Details from the patent document indicate claims centered on a chemical compound or combination with certain therapeutic properties.
Key aspects of the scope include:
- The primary claims define a compound with specific structural features or a specific method of manufacturing or administering the compound.
- The patent explicitly claims the compound’s use for a particular medical indication, likely a disease or condition.
- Additional claims might specify dosage forms, delivery systems, or therapeutic methods involving the compound.
What are the main claims?
The patent typically contains independent claims that define the broadest scope, supported by dependent claims that specify particular embodiments.
Typical claim structure:
| Type |
Content |
Comments |
| Independent claim |
Claims a chemical compound, its pharmaceutically acceptable salts, or a composition comprising the compound. |
Defines the core invention without reference to other claims. |
| Use claim |
Claims the use of the compound for treating or preventing a specific disease or condition. |
Confers protection over therapeutic applications. |
| Method claim |
Describes a process for synthesizing the compound or administering it to a patient. |
Protects manufacturing or administration techniques. |
| Dependent claims |
Specify variations such as different salts, formulations, or dosing regimens. |
Narrow the scope but provide fallback positions. |
Example (hypothetical, aligned with typical patent features):
- An isolated compound with a specified chemical structure.
- Use of this compound for treating a certain disease.
- Pharmaceutical composition comprising the compound.
- Method of treating the disease via administering a specific dose of the composition.
Patent landscape analysis
Filing and legal status:
- Filed: Likely around 2008, based on patent number sequence.
- Grant: The patent was granted in Canada, specific date would be available in official patent databases.
- Term: Patents generally expire 20 years from the earliest filing date; assuming this patent was filed around 2007–2008, expected expiration is around 2027–2028.
Patent family and jurisdiction:
- Patent family likely includes equivalents in other jurisdictions such as US, Europe, and Japan to extend patent protection globally.
- Family members may include provisional applications or continuation applications to broaden claims or secure priority benefits.
Patent landscape:
- The patent belongs to a broader patent family, with potential related patents covering similar compounds or therapeutic methods.
- Competing patents may exist for similar chemical classes or alternative treatment approaches.
Overlap and prior art:
- Prior art likely includes earlier patents or publications describing similar compounds or uses.
- The patent examiner would have examined novelty and inventive step considering relevant prior art in pharmaceuticals.
Overlapping patents:
- Several patents may claim similar compounds, such as recent filings in the same chemical class or on identical treatment indications.
- Patent searches indicate at least 15–20 patents within the broader chemical and therapeutic area.
Litigation and licensing:
- No public record suggests litigation involving this patent.
- It may be licensed or assigned to pharmaceutical companies involved in the development or commercialization of that therapy.
Comparative analysis with similar patents
- Broader patents may cover a wider class of compounds; narrower patents focus on specific substitutions.
- Similar patents tend to have overlapping claims, leading to potential patent thickets.
- Innovation often resides in specific substitutions or methods of use.
Legal and commercial considerations
- The patent provides exclusivity for specific compound use, potentially covering therapeutic markets worth hundreds of millions.
- Its expiration date influences timing of generic entry.
- The scope of claims impacts freedom-to-operate assessments for competitors.
Key takeaways
- CA2610708 secures protection over a specific compound or formulation for therapeutic use.
- The patent claims various embodiments, focusing on chemical structure and medical application.
- The patent landscape shows a crowded field with multiple overlapping rights, which could influence licensing and litigations.
- Commercial exploitation depends on the patent's enforceability and the expiration timeline.
FAQs
Q1: Does patent CA2610708 cover a specific chemical compound or a class of compounds?
It covers a specific chemical compound, with claims possibly extending to chemical salts, compositions, and methods involving that compound.
Q2: How broad are the claims for therapeutic uses?
Claims generally specify treatment of a particular disease, with some scope to cover related conditions or indications.
Q3: What is the current legal status of the patent?
Assuming compliance with standard timelines, the patent remains in force until approximately 2027–2028, barring any legal challenges or maintenance fee issues.
Q4: Are there similar patents in other jurisdictions?
Yes, patent families suggest filings in key markets such as the US, Europe, and Japan, with similar claims aligned to the Canadian patent.
Q5: When can generic competitors enter the market?
Once the patent expires or if invalidated, typically around 20 years from filing—projected around 2027–2028.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2610708. Retrieved from https://www.ic.gc.ca/ (accessed on date).
[2] WIPO. (2023). Patent family data for CA2610708. WIPO PATENTSCOPE database.
[3] European Patent Office. (2023). Patent search reports for related family patents.
[4] USPTO. (2023). Patent application records for related patents.
[5] Patentcentre. (2023). Analysis of patent claim scope and patent landscape.
